Novo Nordisk A/S
NVO US
NVO USNovo Nordisk A/S
United States CompositeCompany Description
- CEO
- Mr. Lars Fruergaard Jorgensen
- Full Time Employees
- 63,370
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Novo Alle 1 Bagsvaerd Denmark 2880
- IPO Date
- Apr 30, 1981
- CIK
- 0000353278
- Website
- www.novonordisk.com
- Business
- Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Company News
Diabetes Drug Made For Under $5 Costs Americans $1,000, Drawing Comparisons To Martin Shrikeli While Juicing Profits for A Drug Giant
Wall Street Analysts Think Novo Nordisk (NVO) Is a Good Investment: Is It?
Wall Street Analysts Think Novo Nordisk (NVO) Is a Good Investment: Is It?
Eli Lilly’s Ozempic Competitors Face Risks. Why the Stock Has More Upside.
Novo Nordisk A/S - share repurchase programme
Here's Why Novo Nordisk (NVO) Fell More Than Broader Market
Here's Why Novo Nordisk (NVO) Fell More Than Broader Market
Take the Zacks Approach to Beat the Market: NVIDIA, Dell, Modine in Focus
Is Novo Nordisk the Best Healthcare Stock for You?
Diversifying Into This Key Market Is 1 More Reason to Buy Novo Nordisk Stock
Ozempic Could Sell at a Profit for $57 a Year, Report Says. It’s Priced at $11,600.
Why Novo Nordisk (NVO) is a Top Stock for the Long-Term
Why Novo Nordisk (NVO) is a Top Stock for the Long-Term
Weight-loss drug deals to drive around 4% of Gerresheimer yearly growth, CEO says
2 Top Biotech Buyout Candidates
Novo Nordisk Under Fire, Post-Ozempic Study
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
Altimmune says weight loss drug minimized muscle loss in trial results that may set it apart
Novo Nordisk's $1,000 diabetes drug Ozempic can be made for less than $5 a month, study suggests
Viking (VKTX) Up 17% on Encouraging Oral Obesity Drug Data